Table 1.B.
Baseline Characteristics (Clinical)
| All participants (N=71) |
Group 1a (n = 19) |
Group 2b (n = 16) |
Group 3c (n = 9) |
Group 4d (n = 27) |
P value | |
|---|---|---|---|---|---|---|
| Ejection fraction, % (Mean±SD) | 26.68 ± 6.61 | 24.86 ± 6.40 | 29.00 ± 8.22 | 28.33 ± 6.49 | 26.02 ± 5.47 | .144 |
| Peak VO2, mg/kg/min (Mean±SD) | 13.72 ± 3.38 | 12.01 ± 2.92 | 13.95 ± 3.09 | 14.50 ± 6.49 | 14.50 ± 3.50 | .144 |
| Six minute walk, feet (Mean±SD) | 1436.86 ± 209.47 | 1457.18 ± 176.63 | 1357.57 ± 167.52 | 1573.25 ± 331.52 | 1420.33 ± 189.50 | .799 |
| NYHA class, N (%) | .539 | |||||
| Class II | 56 (78.9%) | 13 (68.4%) | 14 (87.5%) | 8 (88.9%) | 21 (77.8%) | |
| Class III | 13 (18.3%) | 5 (26.3%) | 1 (6.3%) | 1 (11.1%) | 6 (22.2%) | |
| Class IV | 2 (2.8%) | 1 (5.3%) | 1 (6.3%) | 0 (0%) | 0 (0%) | |
| HF Etiology, Ischemic N (%) | 30 (42.3%) | 7 (36.8%) | 6 (37.5%) | 4 (44.4%) | 13 (48.1%) | .855 |
| History of Hypertension, yes N (%) | 32 (45.1%) | 9 (47.4%) | 8 (50.0%) | 3 (33.3%) | 12 (44.4%) | .873 |
| History of Diabetes, yes N (%) | 22 (31.0%) | 6 (31.6%) | 5 (31.3%) | 4 (44.4%) | 7 (25.9%) | .780 |
| History of Dyslipidemia, yes N (%) | 34 (47.9%) | 9 (47.4%) | 7 (43.8%) | 4 (44.4%) | 14 (51.9%) | .955 |
| History of Depression, yes N (%) | 37 (52.1%) | 6 (16.2%) | 9 (24.3%) | 13 (35.1%) | 9 (24.3%) | .367 |
| Medications use, N (%) | ||||||
| ACE Inhibitors | 52 (73.2%) | 11 (57.9%) | 13 (81.3%) | 7 (77.8%) | 21 (77.8%) | .364 |
| Angiotensin Receptor Blockers | 13 (18.3%) | 5 (26.3%) | 3 (18.8) | 1 (11.1%) | 4 (14.8%) | .718 |
| Beta-Blockers | 50 (70.4%) | 15 (78.9%) | 9 (56.3%) | 7 (77.8%) | 19 (70.4%) | .486 |
| Diuretics | 61 (85.9%0 | 16 (84.2%) | 12 (75.0%) | 8 (88.9%) | 25 (92.6%) | .443 |
| Aldactone | 21 (29.6%) | 5 (26.3%) | 6 (37.5%) | 1 (11.1%) | 9 (33.3%) | .525 |
| Digoxin | 49 (69.0%) | 12 (63.2%) | 12 (75.0%) | 5 (55.6%) | 20 (64.1%) | .646 |
| Anti-depressants | 27 (38.0%) | 3 (11.1%) | 8 (29.6%) | 9 (33.3%) | 7 (25.9%) | .851 |
a
Group 1: participants with improvements in peak VO2 greater that 10%
b
Group 2: participants with improvements in peak VO2 less than 10%
c
Group 3: participants with reductions in peak VO2 less than 10%
d
Group 4: participants with reductions in peak VO2 greater that 10%